Diagnosis and clinical management of Wiskott–Aldrich syndrome: current and emerging techniques. (3rd June 2022)

• Record Type: Journal Article
• Authors: Cavannaugh, Corey; Ochs, Hans D.; Buchbinder, David
• Is Part Of: Expert review of clinical immunology. Volume 18:Number 6(2022)
• Page Start: 609
• Page End: 623
• Publication Date: 2022-06-03
• Subjects: Actin -- combined immunodeficiency -- gene therapy -- hematopoietic stem cell transplantation -- inborn errors of immunity -- primary immunodeficiency; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2022.2074400
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction: Wiskott–Aldrich syndrome (WAS) serves as the prototype of how variants in a gene, which encodes a protein central to actin cytoskeletal homeostasis can manifest clinically in a variety of ways including infection, atopy, autoimmunity, inflammation, bleeding, neutropenia, non-malignant lymphoproliferation, and malignancy. Despite the discovery of the WAS gene almost 30 years ago, our understanding of the pathophysiological mechanisms underlying WAS continues to unfold. Areas covered: This review will provide an overview of the approach to the diagnosis of WAS as well as the management of its associated complications. Advances in the use of allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy as well as the associated challenges unique to WAS will be discussed. Expert opinion: Basic research, combined with clinical research focusing on longitudinal analysis of WAS patients, will help clarify determinants that influence WAS pathogenesis as well as clinical complications and outcomes. Advances in curative approaches including the use of alternative donor HSCT for WAS continue to evolve. Gene therapy employing safer and more effective protocols ensuring full correction of WAS will provide life-saving benefit to WAS patients who are unable to undergo HSCT.